Pictet Asset Management Holding SA Reduces Position in ADMA Biologics Inc $ADMA

Pictet Asset Management Holding SA cut its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 74.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,036 shares of the biotechnology company’s stock after selling 120,798 shares during the period. Pictet Asset Management Holding SA’s holdings in ADMA Biologics were worth $370,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the stock. State Street Corp increased its position in shares of ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after buying an additional 35,614 shares during the period. Sachem Head Capital Management LP increased its stake in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of ADMA Biologics by 36.9% during the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the last quarter. Capital Research Global Investors raised its stake in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC increased its holdings in shares of ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after buying an additional 202,245 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADMA has been the topic of a number of research analyst reports. Mizuho reduced their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group decreased their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price on the stock. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: ADMA is facing repeated securities-fraud class-action promotions and lead-plaintiff reminders, which can weigh on investor confidence and keep legal uncertainty in focus. Article Title
• Negative Sentiment: One notice specifically highlights “channel stuffing” claims in the securities-fraud case, reinforcing allegations of potentially misleading sales practices. Article Title
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not appear to be adding a meaningful trading signal right now.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman purchased 12,500 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $8.01 per share, with a total value of $100,125.00. Following the transaction, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

ADMA Biologics Trading Down 2.0%

ADMA Biologics stock traded down $0.19 during mid-day trading on Friday, reaching $9.08. 2,343,071 shares of the company traded hands, compared to its average volume of 3,311,155. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of 13.35 and a beta of 0.73. The firm’s 50 day moving average price is $8.53 and its 200 day moving average price is $12.66. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting the consensus estimate of $0.19. The business had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.11 EPS. On average, analysts anticipate that ADMA Biologics Inc will post 0.82 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.